Results 161 to 170 of about 71,938 (313)

Cardiopulmonary exercise testing as an integrative approach to explore physiological limitations in Duchenne muscular dystrophy [PDF]

open access: bronze
Meghana Bomma   +16 more
openalex   +1 more source

Dynamic MR of Muscle Contraction During Electrical Muscle Stimulation: Potential Application to the Evaluation of Neuromuscular Diseases

open access: yesNMR in Biomedicine, Volume 38, Issue 12, December 2025.
This exploratory study investigated dynamic MRI during neuromuscular electrical stimulation (NMES) as a biomarker for muscular diseases. Fourteen healthy controls and ten patients with metabolic and myotonic myopathies underwent 3T MRI scanning. Results showed reduced strain and strain buildup rates in patients' soleus muscles compared to controls ...
Francesco Santini   +12 more
wiley   +1 more source

The Roles of EDA2R in Ageing and Disease

open access: yesAging Cell, Volume 24, Issue 12, December 2025.
Elevated expression of the ectodysplasin A2 receptor (EDA2R) has been linked to ageing and disease. We appraise the roles of EDA2R in these processes, exploring mechanisms of action, biomarker potential and therapeutic relevance of EDA2R in multiple contexts. ABSTRACT Ageing is a complex biological process driven, in part, by inflammaging.
Gemma Farrington   +9 more
wiley   +1 more source

Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls [PDF]

open access: hybrid
Joel Iff   +8 more
openalex   +1 more source

Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I/II clinical trial [PDF]

open access: green, 2023
Takami Ishizuka   +11 more
openalex   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

open access: yesCell Proliferation, Volume 58, Issue 12, December 2025.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy